Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Weighted Average) (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $160.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.3% year-over-year to $160.4 million, compared with a TTM value of $160.4 million through Dec 2025, up 9.3%, and an annual FY2025 reading of $160.4 million, up 9.3% over the prior year.
  • Shares Outstanding (Weighted Average) was $160.4 million for Q4 2025 at Xeris Biopharma Holdings, down from $163.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $163.6 million in Q3 2025 and bottomed at $61.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $129.1 million, with a median of $137.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 120.48% in 2022, then rose 1.45% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $79.0 million in 2021, then surged by 71.62% to $135.6 million in 2022, then rose by 1.51% to $137.7 million in 2023, then grew by 6.61% to $146.8 million in 2024, then increased by 9.3% to $160.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for XERS at $160.4 million in Q4 2025, $163.6 million in Q3 2025, and $159.5 million in Q2 2025.